+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Osteoporosis Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

  • ID: 5483599
  • Report
  • November 2021
  • Region: Global
  • 142 Pages
  • IMARC Group

FEATURED COMPANIES

  • Amgen Inc.
  • Company
  • Eli Lilly
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
The global osteoporosis drugs market grew at a CAGR of around 5% during 2015-2020. Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.

The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years. Looking forward, the publisher expects the global osteoporosis drugs market to exhibit moderate growth during the next five years.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global osteoporosis drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product type and route of administration.

Breakup by Product Type:

  • Bisphosphonates
  • Calcitonin
  • Rank Ligand Inhibitor
  • Parathyroid Hormone Therapy (PTH)
  • Selective Estrogen Receptor Modulators (SERMs)
  • Sclerostin Inhibitor
  • Others

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.

Key Questions Answered in This Report:

  • How has the global osteoporosis drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global osteoporosis drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product type?
  • What is the breakup of the market based on the route of administration?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global osteoporosis drugs market and who are the key players?
  • What is the degree of competition in the industry?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • Company
  • Eli Lilly
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Osteoporosis Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product Type
6.1 Bisphosphonates
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Calcitonin
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Rank Ligand Inhibitor
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Parathyroid Hormone Therapy (PTH)
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Selective Estrogen Receptor Modulators (SERMs)
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Sclerostin Inhibitor
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Others
6.7.1 Market Trends
6.7.2 Market Forecast
7 Market Breakup by Route of Administration
7.1 Oral
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Injectable
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Amgen Inc.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Eli Lilly and Company
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.2.3 Financials
13.3.2.4 SWOT Analysis
13.3.3 F. Hoffmann-La Roche AG
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 SWOT Analysis
13.3.4 GlaxoSmithKline Plc
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 Merck & Co. Inc.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.5.4 SWOT Analysis
13.3.6 Novartis AG
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Pfizer Inc.
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Radius Health Inc.
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.9 Teva Pharmaceutical Industries Ltd.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis
13.3.10 UCB S.A.
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 Financials
13.3.10.4 SWOT Analysis
List of Figures
Figure 1: Global: Osteoporosis Drugs Market: Major Drivers and Challenges
Figure 2: Global: Osteoporosis Drugs Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: Osteoporosis Drugs Market: Breakup by Product Type (in %), 2020
Figure 4: Global: Osteoporosis Drugs Market: Breakup by Route of Administration (in %), 2020
Figure 5: Global: Osteoporosis Drugs Market: Breakup by Region (in %), 2020
Figure 6: Global: Osteoporosis Drugs Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 7: Global: Osteoporosis Drugs (Bisphosphonates) Market: Sales Value (in Million US$), 2015 & 2020
Figure 8: Global: Osteoporosis Drugs (Bisphosphonates) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 9: Global: Osteoporosis Drugs (Calcitonin) Market: Sales Value (in Million US$), 2015 & 2020
Figure 10: Global: Osteoporosis Drugs (Calcitonin) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 11: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market: Sales Value (in Million US$), 2015 & 2020
Figure 12: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 13: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market: Sales Value (in Million US$), 2015 & 2020
Figure 14: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 15: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market: Sales Value (in Million US$), 2015 & 2020
Figure 16: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 17: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market: Sales Value (in Million US$), 2015 & 2020
Figure 18: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 19: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million US$), 2015 & 2020
Figure 20: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 21: Global: Osteoporosis Drugs (Oral) Market: Sales Value (in Million US$), 2015 & 2020
Figure 22: Global: Osteoporosis Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 23: Global: Osteoporosis Drugs (Injectable) Market: Sales Value (in Million US$), 2015 & 2020
Figure 24: Global: Osteoporosis Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 25: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million US$), 2015 & 2020
Figure 26: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 27: Asia-Pacific: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 28: Asia-Pacific: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 29: Asia-Pacific: Osteoporosis Drugs Market: Breakup by Country (in %), 2020
Figure 30: China: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 31: China: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 32: Japan: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 33: Japan: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 34: India: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 35: India: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 36: South Korea: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 37: South Korea: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 38: Australia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 39: Australia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 40: Indonesia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 41: Indonesia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 42: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 43: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 44: Europe: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 45: Europe: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 46: Europe: Osteoporosis Drugs Market: Breakup by Country (in %), 2020
Figure 47: Germany: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 48: Germany: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 49: France: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 50: France: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 51: United Kingdom: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 52: United Kingdom: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 53: Italy: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 54: Italy: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 55: Spain: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 56: Spain: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 57: Russia: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 58: Russia: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 59: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 60: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 61: Latin America: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 62: Latin America: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 63: Latin America: Osteoporosis Drugs Market: Breakup by Country (in %), 2020
Figure 64: Brazil: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 65: Brazil: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 66: Mexico: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 67: Mexico: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 68: Others: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 69: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 70: Middle East and Africa: Osteoporosis Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 71: Middle East and Africa: Osteoporosis Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 72: Middle East and Africa: Osteoporosis Drugs Market: Breakup by Country (in %), 2020
Figure 73: Global: Osteoporosis Drugs Industry: SWOT Analysis
Figure 74: Global: Osteoporosis Drugs Industry: Value Chain Analysis
Figure 75: Global: Osteoporosis Drugs Industry: Porter's Five Forces Analysi
List of Tables
Table 1: Global: Osteoporosis Drugs Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Osteoporosis Drugs Market Forecast: Breakup by Product Type (in Million US$), 2021-2026
Table 3: Global: Osteoporosis Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2021-2026
Table 4: Global: Osteoporosis Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 5: Global: Osteoporosis Drugs Market: Competitive Structure
Table 6: Global: Osteoporosis Drugs Market: Key Players
Note: Product cover images may vary from those shown
  • Amgen Inc.
  • Eli Lilly
  • Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Radius Health Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
Note: Product cover images may vary from those shown

Loading
LOADING...